Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Early Access of MK0518 in Combination With an Optimized Background Antiretroviral Therapy (0518-023)

This treatment has been approved for sale to the public.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00377065
First received: September 14, 2006
Last updated: October 31, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This treatment has been approved for sale to the public.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given